Between evidence and new perspectives on the current state of the multimodal approach to gastric cancer: Is there still a role for radiation therapy?

Table 3 The main phase I/II trials in gastric cancer that evaluate the preoperative therapy

Trial	Year/type	N° of patients	Treatment schedule	Median FU	Severe toxicity	Clinical efficacy	Survival	Limits/characteristics
Matsuda[51]	2014/ Phase I	9	SP q15 + RT	NR	Diarrhea (11.1) Anorexia (11.1)	PR (78) SD (22)	NR	MTD: CDDP 25 mg/m2
Michel[37]	2014/ Phase II	42	FOLFIRIx4→CRT	38.1 mo	During FOLFIRI (26.2) During RT (19.1)	CR (8.6) Median PFS: 12.3 mo	Median OS: 26.4 mo	Reduced feasibility, 73.8% of patients completed the schedule
Trip[38]	2014/ Phase I/II	25	CBDCA-PTX + RT	NR	Nausea (4) Anorexia (4) Esophagitis (4) Leukopenia (12) Febrile neutropenia (4) Thrombosis (4) Fatigue (4)	CR (16) PR (52)	Median OS: 15 mo
Wydmanski[40]	2014/ Phase II	13	5FU + RT	30.1 mo	Nausea (7.7) Vomiting (7.7) Thrombocytopenia (92.3) Leukopenia (7.7)	NR	Median OS: 17.1 mo 3-yr OS: 48%	Inoperable patients. High rate of severe thrombocytopenia, with 5FU 325 mg/m2 d1-5 and 29-33
Liu[52]	2017/ Phase II	40	SOXx1→S-1 + RT → SOXx1 → surgery→SOXx4	26.5 mo	Leukopenia (10) Neutropenia (10) Thrombocytopenia (2.5)	CR (7.5) PR (30) SD (40) PD (12.5) 2-yr DFS: 47%	2-yr OS: 56%	Treatment compliance: 87.5%

CRT: Chemoradiotherapy; RT: Radiotherapy; CR: Complete response; OS: Overall survival; NR: Not reported; PR: Partial response; SD: Stable disease; MTD: Maximum tolerated dose; PD: Progressive disease; DFS: Disease-free survival; PFS: Progression-free survival.